Covaxin Phase 3 Trial Update: Bharat Biotech's COVID-19 Vaccine Data Shows 77% Efficacy, Says Lancent
The Lancet, a prestigious medical journal has said that Covaxin's phase 3 data demonstrates 77.8% efficacy against the COVID-19.
After a week of WHO granting the emergency Use Listing (EUL) to Bharat Biotech's Covaxin, The Lancet, a prestigious medical journal has said that Covaxin's phase 3 data demonstrates 77.8% efficacy against the COVID-19.
Check the tweet here:
The Lancet peer-review confirms the efficacy analysis of Bharat Biotech's Covaxin - As per phase-three clinical trials data, Covaxin demonstrates 77.8% efficacy against symptomatic COVID19 pic.twitter.com/6tnUneq3e6
— ANI (@ANI) November 12, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)
(The above story first appeared on LatestLY on Nov 12, 2021 08:02 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
